| 0 (0%) | 01-19 18:52 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 37.22  |
1-year : | 43.47 |
| Resists | First : | 31.87 |
Second : | 37.22 |
| Pivot price | 29.21 |
|||
| Supports | First : | 29.16 |
Second : | 27.5 |
| MAs | MA(5) : | 30.44 |
MA(20) : | 29 |
| MA(100) : | 29.5 |
MA(250) : | 30.13 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 92 |
D(3) : | 81.7 |
| RSI | RSI(14): 70.4 |
|||
| 52-week | High : | 36.45 | Low : | 25.17 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ALKS ] has closed Bollinger Bands are 32.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.92 - 32.05 | 32.05 - 32.18 |
| Low: | 30.84 - 30.97 | 30.97 - 31.11 |
| Close: | 31.41 - 31.64 | 31.64 - 31.88 |
Mon, 19 Jan 2026
Alkermes (ALKS) Is Up 6.8% After FDA Breakthrough Tag for Narcolepsy Drug Candidate Alixorexton - What's Changed - simplywall.st
Sun, 18 Jan 2026
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton, Potentially Accelerating Development - Intellectia AI
Sun, 18 Jan 2026
Alkermes (ALKS) Is Up 6.6% After FDA Breakthrough Tag for Narcolepsy Drug Alixorexton - Yahoo Finance
Sun, 18 Jan 2026
Alkermes (ALKS) Valuation Check After Recent Share Price Momentum And Undervaluation Signals - simplywall.st
Thu, 15 Jan 2026
Piper Sandler Raises Price Target for ALKS to $45, Reiterates Ov - GuruFocus
Thu, 15 Jan 2026
Alkermes PLC (ALKS) Stock Price Up 3.16% on Jan 15 - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 165 (M) |
| Shares Float | 163 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 106.2 (%) |
| Shares Short | 20,030 (K) |
| Shares Short P.Month | 17,300 (K) |
| EPS | 2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.5 |
| Profit Margin | 22.2 % |
| Operating Margin | 22.6 % |
| Return on Assets (ttm) | 9.9 % |
| Return on Equity (ttm) | 22.3 % |
| Qtrly Rev. Growth | 4.1 % |
| Gross Profit (p.s.) | 7.93 |
| Sales Per Share | 9.2 |
| EBITDA (p.s.) | 2.35 |
| Qtrly Earnings Growth | -12.2 % |
| Operating Cash Flow | 541 (M) |
| Levered Free Cash Flow | 342 (M) |
| PE Ratio | 15.73 |
| PEG Ratio | 0 |
| Price to Book value | 3.01 |
| Price to Sales | 3.43 |
| Price to Cash Flow | 9.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|